Press release
Top 30 Indonesian Paracetamol Public Companies Q3 2025 Revenue & Performance
1) Overall companies performance (Q3 2025 snapshot)Kalbe Farma
Kimia Farma
Tempo Scan Pacific
Darya-Varia Laboratoria
Indofarma
Phapros
Pyridam Farma
Merck Indonesia
Sido Muncul
Enseval Putera Megatrading
Soho Global Health
Dexa Medica
Industri Jamu & Farmasi Sido Muncul
Kalbe Consumer Health subsidiaries
Hexpharm Jaya Laboratories
Dankos Farma
Sanbe Farma
Novell Pharmaceutical Laboratories
Bernofarm
Guardian Pharmatama
Combiphar
Otto Pharmaceutical Industries
Graha Farma
Erlimpex
Ifars Pharmaceutical Laboratories
Lapi Laboratories
Caprifarmindo Laboratories
Global Multi Pharmalab
Mahakam Beta Farma
Surya Dermato Medica Laboratories
2) Revenue results of major public companies in Indonesia summarized (per company)
1. Kalbe Farma remains the largest pharmaceutical player (USD 2B revenue scale). Q3/9M 2025 revenue: USD 1.51.7B Net profit margin: 1112% Performance driven by: OTC portfolio (including analgesics like paracetamol), strong distribution network. Maintained stable growth through volume expansion
2. Tempo Scan Pacific Q3/9M 2025 net profit: IDR 1.14T (USD 68.3M) Revenue growth supported by OTC + prescription drugs. Paracetamol-based products contributed to resilient consumer health segment
3. Darya-Varia Laboratoria Q3 2025 net profit: IDR 164.3B (USD 9.8M) branded generics & OTC. Margin stability despite competitive pricing pressure
4. Indofarma Q3/9M 2025 net loss: IDR -127.1B (USD -7.6M) Ongoing restructuring; still weak profitability. Paracetamol remains commodity product with low margins
5. Kimia Farma Q3 2025: revenue stable; profitability under pressure. Key driver: generic drugs & government contracts. Margins impacted by pricing controls and cost inflation
6. Phapros Q3 2025: moderate revenue growth, generics incl. analgesics. Strong presence in government procurement channel
7. Pyridam Farma Q3 2025: revenue growth driven by consumer health products. Expansion in OTC boosted paracetamol segment indirectly
8. Merck Indonesia Q3 2025: stable earnings; focus on specialty + OTC. Higher-margin portfolio reduces reliance on commoditized drugs
9. Sido Muncul 2025 net profit: IDR 818.5B (USD 49.0M). While herbal-focused, competes in symptom relief category vs paracetamol
10. Enseval Putera Megatrading 2025 net profit: IDR 603.4B (USD 36.2M). Revenue: IDR 24.4T (USD 1.5B). Distribution strength critical for paracetamol volume sales
3) Key trends & insights from Q3 2025
Strong OTC demand resilience driven by population growth and self-medication trends
Paracetamol remains a high-volume, low-margin commodity drug
Increasing competition from generics compressing pricing
Heavy reliance on imported API (p-aminophenol) exposes cost risks
Distribution networks (e.g., Enseval) are critical competitive advantage
Rising demand for combination drugs (flu, cold, fever)
Shift toward fast-acting and extended-release formulations
Government policies and patent dynamics influencing market accessibility
4) Outlook for Q4 2025 and beyond
Continued mid-single digit growth (57%) expected
Margin pressure likely due to API cost volatility and pricing competition
Expansion of domestic pharmaceutical manufacturing capacity
Increased focus on value-added OTC formulations and branded generics differentiation
Potential supply chain disruption from China API policy changes
Growth supported by universal healthcare (JKN program) and expanding middle class demand
5) Conclusion
The Indonesian paracetamol industry in Q3 2025 reflects a mature, volume-driven pharmaceutical segment anchored by large integrated players like Kalbe Farma and Tempo Scan Pacific. While demand remains structurally strong due to the essential nature of paracetamol, the industry faces persistent margin compression, API dependency risks, and intense generic competition. Looking ahead, companies that can differentiate through branding, distribution strength, and formulation innovation rather than pure commodity production will be best positioned to capture sustainable value in Indonesias expanding healthcare market.
Contact Information:
Tel: +1 626 2952 442 (US) ; +86-1082945717 (China)
+62 896 3769 3166 (Whatsapp)
Email: willyanto@qyresearch.com; global@qyresearch.com
Website: www.qyresearch.com
About QY Research
QY Research has established close partnerships with over 71,000 global leading players. With more than 20,000 industry experts worldwide, we maintain a strong global network to efficiently gather insights and raw data.
Our 36-step verification system ensures the reliability and quality of our data. With over 2 million reports, we have become the world's largest market report vendor. Our global database spans more than 2,000 sources and covers data from most countries, including import and export details.
We have partners in over 160 countries, providing comprehensive coverage of both sales and research networks. A 90% client return rate and long-term cooperation with key partners demonstrate the high level of service and quality QY Research delivers.
More than 30 IPOs and over 5,000 global media outlets and major corporations have used our data, solidifying QY Research as a global leader in data supply. We are committed to delivering services that exceed both client and societal expectations.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Top 30 Indonesian Paracetamol Public Companies Q3 2025 Revenue & Performance here
News-ID: 4482460 • Views: …
More Releases from QY Research
Reactive Power, Real Returns: Investment Thesis for the Global Three-Phase Capac …
The global three-phase capacitor market is undergoing a non-linear value inflection, transitioning from a historically volume-driven electrical component segment into a capital-intensive, specification-driven infrastructure layer. This shift is primarily driven by the increasing complexity of industrial loads, renewable integration, and grid instability challenges, all of which demand higher-performance reactive power compensation systems. Capacitors are no longer commoditized passive components; instead, they are embedded into intelligent power management architectures, raising both…
Infant Gut Health as an Investment Theme: Asia-Pacific Manufacturing Scale Meets …
The Infant Probiotic Strains market is undergoing a non-linear value inflection, transitioning from a historically volume-driven nutraceutical segment into a capital-intensive, clinically validated biotech-adjacent category. In 2025, the market is valued at USD 118 million, with projections reaching USD 191 million by 2032, implying a 7.1% CAGR. This growth is not merely demand expansion but reflects a structural repricing of high-efficacy strains particularly those with documented benefits in immunity modulation,…
Fiber Optic Drones: From Tactical Deployment to Capital-Intensive Infrastructure
The global Fiber Optic Drone market is entering a phase of non-linear value inflection, driven by a structural pivot from standalone drone units toward integrated tethered systems with secure, uninterrupted data transmission. Unlike traditional RF-based UAVs, fiber optic drones rely on physical tethering for real-time data transfer, power supply stability, and anti-jamming capabilities features increasingly demanded in military, energy, and critical infrastructure surveillance. This shift is compressing commoditized hardware margins…
From Fresh Convenience to Industrial Scale: The Structural Inflection in RTE Col …
The global Ready-to-Eat (RTE) salads and cold meals market is entering a phase of non-linear value inflection, transitioning from fragmented, labor-intensive food preparation into a capital-intensive, systematized food manufacturing industry. Historically driven by volume throughput and short shelf-life distribution, value capture is now migrating toward integrated cold-chain logistics, automated processing lines, and proprietary packaging technologies. This transition is compressing smaller operators while enabling scaled producers to extract higher margins through…
More Releases for Farma
Gumboro Disease Market to Witness Comprehensive Growth by 2032 | Ceva, ROMVAC Co …
New Report Highlights Key Insights in the Gumboro Disease Market (2025-2032)
Coherent Market Insights has published a detailed report titled "Gumboro Disease Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032." This study offers a deep dive into the Gumboro Disease industry, covering market trends, growth drivers, challenges, competitive landscape, and regional insights. With 134 figures, tables, and charts, the report provides a data-rich analysis to help businesses understand the…
Casual Wear Insoles Market | Aetrex Worldwide, Bauerfeind, Currex GmbH, FAES FAR …
The global casual wear insoles market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the casual wear insoles market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Heart Health Functional Food Market - Marico, Kellogg, Raisio, Nestle, Kalbe Far …
Heart Health Functional Food Market research market report is the outcome of persistent efforts led by knowledgeable forecasters, innovative analysts, and brilliant researchers who conduct detailed and diligent research on different markets, trends, and emerging opportunities in the consecutive direction for the business needs. Systematic investment analysis is also underlined in this report which forecasts upcoming opportunities for the market players.
Click Here For Free Sample + Related Graphs of the…
Tuberculosis Drugs Market to Eyewitness Massive Growth by EIKEN CHEMICAL, Sandoz …
Latent TB occurs when a person has the TB bacteria within their body, but the bacteria are present in very small numbers. They are kept under control by the body’s immune system and do not cause any symptoms.
People with latent TB do not feel sick and are not infectious. They cannot pass the bacteria on to other people. In addition they will usually have a normal chest x-ray and a…
Convalescent Plasma Therapy Market Size, Industry Growth And Top Leaders - Bio F …
The Business Research Company offers “Convalescent Plasma Therapy Market Global Report 2020-30: Covid 19 Implications And Growth" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by…
Alpha-Synuclein Inhibitor Therapeutics -Clinical Trials & Results | AC Immune, N …
Alpha-synuclein is a protein that is abundantly found in the brain. The minimal amount of alpha-synuclein is also found in the heart and other tissues. The protein is prominently found at the tips of the nerve cells. It helps in the maintaining supply of the synaptic vesicle in presynaptic terminals.
Download the sample report @ https://www.pharmaproff.com/request-sample/1170
In addition, the alpha-synuclein protein also helps in release of dopamine. The protein comprised of…
